Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

345
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
345
Standards of Care II01:19

Standards of Care II

1.2K
Nurses bear specific legal responsibilities under several federal statutes, including:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrophysiological Changes in Resting-State EEG Following REAC BWO-G_B Neurobiological Modulation in Healthy Adults: A Spectral and Multivariate Exploratory Study.

Brain sciences·2026
Same author

Endogenous Bioelectrical Modulation of Longevity-Associated and Inflammatory Signaling Pathways in Human Dermal Fibroblasts Following the REAC ACT-IBZ Protocol.

Life (Basel, Switzerland)·2026
Same author

Reversal of Endogenous Bioelectrical Network Collapse in Advanced Childhood Cerebral X-Linked Adrenoleukodystrophy.

Neurology international·2026
Same author

Endogenous Bioelectrical Modulation by REAC Metabolic Optimization-IBZ Modulates SIRT1, PPAR-γ, and Metabolic Signaling Pathways in Human Fibroblasts.

Cells·2026
Same author

Targeted Endogenous Bioelectric Modulation in Autism Spectrum Disorder: Real-World Clinical Outcomes of the REAC BWO Neurodevelopment-Autism Protocol.

Journal of clinical medicine·2025
Same author

REAC Neurobiological Modulation With Neuro Postural Optimization (NPO) and Neuro Muscular Optimization (NMO) in Early Post-stroke Recovery: Functional Outcomes, Mechanistic Rationale, and Implications for Neurorehabilitation.

Cureus·2025

Related Experiment Video

Updated: Mar 15, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Clinical Performance of REAC-Based ACT, CO, and MO-IBZ Protocols in Routine Practice: A Prospective Real-World

Vania Fontani1,2,3, Arianna Rinaldi1,2,3, Bruna Lombardi3

  • 1Department of Reparative and Regenerative Medicine, Rinaldi Fontani Institute, 50144 Florence, Italy.

Journal of Clinical Medicine
|March 14, 2026
PubMed
Summary

Anti-inflammatory cellular treatment (ACT), circulatory optimization (CO), and metabolic optimization (MO) significantly reduced pain and improved symptoms in patients with chronic low-grade inflammation. These REAC-based treatments demonstrated good tolerability and clinical effectiveness.

Keywords:
biomodulationchronic low-grade inflammationfatiguepainpatient-reported outcomespost-market clinical follow-upreal-world evidencesleep disturbance

More Related Videos

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K
Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
09:57

Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria

Published on: December 14, 2016

10.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Area of Science:

  • Biomedical engineering
  • Regenerative medicine
  • Inflammation research

Background:

  • Chronic low-grade inflammation is linked to persistent pain, sleep issues, fatigue, and reduced well-being.
  • Non-invasive REAC-based biomodulation protocols like ACT, CO, and MO are used within the Inside Blue Zone (IBZ) framework.
  • Limited real-world data exists on patient-reported outcomes for these IBZ protocols.

Purpose of the Study:

  • To evaluate pain intensity and symptom burden in patients undergoing sequential ACT, CO, and MO.
  • To assess patient-reported outcomes within a Post-Market Clinical Follow-Up (PMCF) framework.
  • To determine the clinical performance and tolerability of REAC-based biomodulation for chronic inflammatory conditions.

Main Methods:

  • Prospective observational PMCF study involving 50 subjects.
  • Sequential administration of anti-inflammatory cellular treatment (ACT), circulatory optimization (CO), and metabolic optimization (MO).
  • Pain assessed using Visual Analog Scale (VAS) at baseline, end of treatment, and follow-up; secondary outcomes analyzed by severity categories.

Main Results:

  • Significant VAS pain score reduction from baseline to end of treatment (p < 0.001), sustained at follow-up.
  • 78% of subjects met responder criteria for pain reduction.
  • Secondary outcomes showed a shift towards lower severity categories for sleep disturbance, fatigue, and well-being.

Conclusions:

  • Sequential ACT, CO, and MO protocols effectively reduce pain and improve symptom burden in chronic low-grade inflammatory conditions.
  • The REAC-based approach demonstrated clinically meaningful improvements and good tolerability.
  • Findings support the clinical utility of these non-invasive biomodulation strategies for managing chronic inflammation-related symptoms.